Advances of MUC1 as a target for breast cancer immunotherapy

Publication:
Advances of MUC1 as a target for breast cancer immunotherapy

dc.contributor.author	Yang, E.	es
dc.contributor.author	Hu, X.F.	es
dc.contributor.author	Xing, P.X.
dc.date.accessioned	2012-05-21T12:10:42Z
dc.date.available	2012-05-21T12:10:42Z
dc.date.issued	2007
dc.description.abstract	MUC1 is a potential target in breast cancer immunotherapy as MUC1 is overexpressed in breast cancer, and is absent or expressed in low level in normal mammary gland. In addition, MUC1 is mostly aberrantly underglycosylated in cancer and the antigens on the cancer surface are different from normal cell. Therefore targeting MUC1 for cancer immunotherapy can exploit the difference between cancer and normal cells, and eliminating the cancerous cells while leaving the normal mammary cells unharmed. This review will focus on the recent advance of MUC1 breast cancer immunotherapy currently being investigated.	es
dc.format	application/pdf	es
dc.format.extent	17	es
dc.identifier.issn	0213-3911	es
dc.identifier.uri	http://hdl.handle.net/10201/27626
dc.language	eng	es
dc.publisher	Murcia : F. Hernández	es
dc.relation.ispartof	Histology and histopathology	es
dc.rights	info:eu-repo/semantics/openAccess	es
dc.subject	Immunotherapy	es
dc.subject	Breast cancer	es
dc.subject.other	616 - Patología. Medicina clínica. Oncología	es
dc.title	Advances of MUC1 as a target for breast cancer immunotherapy	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es

Now showing 1 - 1 of 1

Sin licencia Creative Commons.